Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Equity (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Return on Equity for 12 consecutive years, with 4.72% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 695.0% to 4.72% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4.72% through Dec 2025, up 695.0% year-over-year, with the annual reading at 9.89% for FY2025, 840.0% down from the prior year.
  • Return on Equity hit 4.72% in Q4 2025 for Coherus Oncology, up from 3.25% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 45.79% in Q2 2022 to a low of 11.49% in Q2 2025.
  • Historically, Return on Equity has averaged 2.0% across 5 years, with a median of 0.22% in 2024.
  • Biggest five-year swings in Return on Equity: skyrocketed 4697bps in 2022 and later plummeted -4436bps in 2023.
  • Year by year, Return on Equity stood at 2.51% in 2021, then skyrocketed by 199bps to 2.49% in 2022, then plummeted by -42bps to 1.45% in 2023, then tumbled by -253bps to 2.23% in 2024, then surged by 312bps to 4.72% in 2025.
  • Business Quant data shows Return on Equity for CHRS at 4.72% in Q4 2025, 3.25% in Q3 2025, and 11.49% in Q2 2025.